#United States #FDA Approval #Reckitt #Nutley #Mucinex®

Reckitt's Major Milestone: Mucinex® 12HR Cold & Fever

In a significant breakthrough for the cold and flu medication market, Reckitt has successfully received FDA approval for Mucinex® 12HR Cold & Fever Multi-Symptom. This innovative product marks the first new over-the-counter (OTC) cold and flu treatment in the United States in 14 years. Launched to provide long-lasting relief, this formulation is particularly noteworthy in light of the rising burden that cold and flu illnesses pose to Americans.

Addressing a Critical Need

The approval is timely, aligning with a growing recognition of the healthcare challenges posed by seasonal illnesses. With flu seasons generating millions of office visits and school absences annually, the need for effective self-care solutions has never been more pressing. According to the CDC, recent flu seasons have seen staggering illness estimates, with millions affected each year. This makes the launch and accessibility of Mucinex® 12HR a substantial addition to the consumer health landscape.

Innovative Formulation and Long-Lasting Relief

What truly sets Mucinex® 12HR apart is its combination of three active ingredients: guaifenesin, a well-known expectorant; dextromethorphan HBr, a cough suppressant; and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID). This unique combination enables the product to target multiple symptoms utilizing a patented bilayer tablet design, providing relief that lasts up to 12 hours. This innovative approach aims to meet the top unmet need in the cold and flu category—long-lasting symptom relief.

Jérôme Lemaire, President of Reckitt North America, emphasized that this launch underscores their commitment to producing scientifically validated, everyday health solutions. The goal is not only to enhance consumer choices but also to simplify health management for families.

A Commitment to Science and Consumer Needs

The path to this approval reflects a decade of rigorous scientific research and collaboration with regulatory bodies, demonstrating Reckitt's dedication to understanding consumer needs. Angela Naef, Ph.D., Chief Research & Development Officer at Reckitt, noted that this achievement is the result of extensive research aimed at combining the science of cold and flu symptom relief with practical, consumer-friendly solutions.

Mucinex® 12HR Cold & Fever Multi-Symptom has now become a cornerstone for users seeking effective relief, thanks to its innovative tablet design and scientifically-backed formulation. The anticipated impact of this product is significant, as it promises to alleviate the troublesome symptoms of cough, congestion, fever, and body aches, all in a single dose.

Expanding Mucinex® Product Family

This launch does not just add another product to the Mucinex line; it enhances Reckitt's overall portfolio of healthcare solutions, positioning the brand as a leader driven by consumer trust and scientific innovation. For more than 20 years, the Mucinex® brand has been synonymous with reliability in managing cold symptoms, and the introduction of Mucinex® 12HR reflects a natural evolution of this trusted name. Consumers nationwide can now easily access this new formulation at retailers.

Conclusion

Reckitt's Mucinex® 12HR Cold & Fever Multi-Symptom exemplifies how innovation can forge new paths in healthcare, meeting both current consumer needs and setting new industry standards in OTC medications. With a focus on delivering long-lasting relief, Reckitt not only provides a solution for managing cold and flu but also empowers individuals to maintain their daily routines during illness. As the Mucinex® family continues to grow, the future looks promising for consumer health innovations driven by scientific research and dedicated efforts.

• ---